Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
10 May 2013 EMCTO 2013 News: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced/metastatic NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
10 May 2013 EMCTO 2013 News: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
10 May 2013 EMCTO 2013 News: Findings support the value of tumour rebiopsy in NSCLC patients Lung and other thoracic tumours
10 May 2013 EMCTO 2013 News: Enobosarm improves muscle wasting experienced by patients with NSCLC Palliative and supportive care - Lung and other thoracic tumours
30 Apr 2013 European Medicines Agency recommends granting a conditional marketing authorisation for vismodegib Melanoma - Anticancer agents & Biologic therapy
29 Apr 2013 Adequate supply level has been restored in all EU Member States and pegylated doxorubicin hydrochloride can now be used again without restrictions Breast cancer - Gynaecologic malignancies - Anticancer agents & Biologic therapy
29 Apr 2013 European Medicines Agency recommends granting a marketing authorisation for enzalutamide Genitourinary cancers - Anticancer agents & Biologic therapy
26 Apr 2013 New European system for medicines under additional monitoring Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
25 Apr 2013 Access to cancer medicines in low- and middle-income countries Bioethics, legal and economic issues
24 Apr 2013 A retrospective analysis suggests that patients with NSCLC who harbour specific HER2 mutations may benefit from certain anti-HER2 treatments Personalised medicine - Lung and other thoracic tumours
23 Apr 2013 New research characterises effectiveness and variability in patient recruitment and retention practices Bioethics, legal and economic issues
22 Apr 2013 Cancer cachexia in the era of obesity Palliative and supportive care
17 Apr 2013 Novel AKT pathway inhibitor, ARQ 092, demonstrates safety, effective target inhibition Anticancer agents & Biologic therapy
17 Apr 2013 AKT inhibitor AZD5363 well tolerated, yielded partial response in some patients with advanced solid tumours Anticancer agents & Biologic therapy
15 Apr 2013 Are the elderly excluded from practice-changing trials in advanced NSCLC? Cancer in Special Situations - Lung and other thoracic tumours